MX2020004072A - Monitoreo de terapia bajo tratamiento con un aglutinante anti-adrenomodulina (adm). - Google Patents

Monitoreo de terapia bajo tratamiento con un aglutinante anti-adrenomodulina (adm).

Info

Publication number
MX2020004072A
MX2020004072A MX2020004072A MX2020004072A MX2020004072A MX 2020004072 A MX2020004072 A MX 2020004072A MX 2020004072 A MX2020004072 A MX 2020004072A MX 2020004072 A MX2020004072 A MX 2020004072A MX 2020004072 A MX2020004072 A MX 2020004072A
Authority
MX
Mexico
Prior art keywords
adrenomedullin
adm
binder
under treatment
monitoring under
Prior art date
Application number
MX2020004072A
Other languages
English (en)
Inventor
Andreas Bergmann
Joachim Struck
Original Assignee
Adrenomed Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adrenomed Ag filed Critical Adrenomed Ag
Publication of MX2020004072A publication Critical patent/MX2020004072A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La materia objeto de la presente invención es un método para monitorear una terapia en un individuo, en el cual el individuo está bajo tratamiento con un aglutinante anti-adrenomedulina (ADM) que se selecciona a partir del grupo que comprende un anticuerpo, fragmento de anticuerpo y/o andamio no lg. que comprende determinar el nivel de un fragmento de pre-pro-adrenomedulina que se selecciona a partir del grupo que comprende proadreonomedulina de la región media (MR-proADM). proadrenomedulina C-terminal (CT-proADM) y/o el péptido de 20 aminoácidos N-terminal de proadrenomedulina (PAM) o fragmentos de los mismos en un fluido corporal obtenido a partir de dicho individuo: y correlacionar el nivel de dicho fragmento de pre-pro-adrenomedulina con el estado de salud clínico/médico del individuo y/o el riesgo de un resultado adverso y/o el requerimiento de adaptar las medidas terapéuticas.
MX2020004072A 2017-10-18 2018-10-18 Monitoreo de terapia bajo tratamiento con un aglutinante anti-adrenomodulina (adm). MX2020004072A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17197177 2017-10-18
PCT/EP2018/078647 WO2019077082A1 (en) 2017-10-18 2018-10-18 SURVEILLANCE OF THERAPY UNDER TREATMENT WITH ANTI-ADRENOMEDULIN BINDER (ADM)

Publications (1)

Publication Number Publication Date
MX2020004072A true MX2020004072A (es) 2020-07-28

Family

ID=60301753

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004072A MX2020004072A (es) 2017-10-18 2018-10-18 Monitoreo de terapia bajo tratamiento con un aglutinante anti-adrenomodulina (adm).

Country Status (10)

Country Link
US (1) US20220268761A1 (es)
EP (1) EP3698134A1 (es)
JP (1) JP2021500548A (es)
CN (1) CN111480076A (es)
AU (1) AU2018350861A1 (es)
BR (1) BR112020005682A2 (es)
CA (1) CA3079112A1 (es)
MX (1) MX2020004072A (es)
SG (1) SG11202002268XA (es)
WO (1) WO2019077082A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7291688B2 (ja) * 2017-09-13 2023-06-15 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 重篤患者における腎置換療法のための指標としてのアドレノメズリン前駆体
WO2021038078A1 (en) * 2019-08-30 2021-03-04 4TEEN4 Pharmaceuticals GmbH Therapy guidance and/or therapy monitoring for treatment of shock
EP3871689A1 (en) * 2020-02-26 2021-09-01 sphingotec GmbH Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c
CA3168978A1 (en) * 2020-02-27 2021-09-02 Andreas Bergmann Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock
CN115244401A (zh) * 2020-02-27 2022-10-25 4Teen4制药有限公司 用于在休克患者中进行nt-adm抗体的治疗指导、监测和分层的dpp3
US20240255531A1 (en) 2021-05-07 2024-08-01 Sphingotec Gmbh Mature adrenomedullin for therapy stratification of corticosteroids in critically ill patients
CN119072492A (zh) * 2022-03-15 2024-12-03 艾德里诺医药公司 抗肾上腺髓质素（adm）抗体或抗adm抗体片段的稳定水性制剂
CN122374646A (zh) 2023-12-22 2026-07-10 Pam治疗诊断有限公司 ADM-Gly作为脓毒症早期预测标志物

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
JP2774769B2 (ja) 1993-04-26 1998-07-09 賢治 寒川 アドレノメデュリン
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
EP1214600B1 (en) * 1999-09-10 2005-12-21 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Determination of adrenomedullin-binding proteins
CN1628126A (zh) 2001-08-30 2005-06-15 比奥雷克西斯药物公司 经修饰的运铁蛋白融合蛋白
PT2298278E (pt) 2002-06-07 2016-02-25 Dyax Corp Prevenção e redução da perda de sangue e resposta inflamatória
DE10316583A1 (de) * 2003-04-10 2004-10-28 B.R.A.H.M.S Aktiengesellschaft Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung
WO2004097423A1 (en) 2003-04-25 2004-11-11 Genova Ltd. Secreted polypeptide species reduced cardiovascular disorders
CA2543360A1 (en) 2003-10-24 2005-05-06 Joost A. Kolkman Ldl receptor class a and egf domain monomers and multimers
US20100028995A1 (en) 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
US20070280886A1 (en) 2004-09-09 2007-12-06 Bayer Healthcare Ag Diagnostics and Therapeutics for Diseases Associated with Adrenomedullin Receptor (Amdr)
AU2005287557B2 (en) 2004-09-21 2011-10-13 Biontech Ag Use of microproteins as tryptase inhibitors
EP1731910A1 (en) * 2005-06-07 2006-12-13 F. Hoffmann-La Roche Ag Use of NT-proANP and NT-proBNP for diagnosing cardiac diseases
DE102006060112A1 (de) * 2006-12-20 2008-06-26 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM
ES2373832T3 (es) 2007-12-19 2012-02-09 Affibody Ab Polipéptido derivado de proteína a y capaz de unirse a pdgf.
NZ592591A (en) 2008-11-03 2012-04-27 Molecular Partners Ag Binding proteins comprising ankyrin repeast domains that inhibit the vegf-a receptor interaction
CA2772162C (en) 2009-08-27 2018-05-22 Covagen Ag Anti-il-17a fynomers and medical uses thereof
BR112012014417B1 (pt) 2009-12-14 2021-11-09 Scil Proteins Gmbh Proteínas ubiquitinas modificadas tendo uma atividade de ligação específica para o extradomínio b de fibronectina
AU2011263786B2 (en) 2010-06-08 2014-11-13 Astrazeneca Ab Tear lipocalin muteins binding IL-4 R alpha
BR112014011670B1 (pt) * 2011-11-16 2021-05-25 Adrenomed Ag anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou um arcabouço de proteína não-igg anti-adm que se liga à adrenomedulina e formulação farmacêutica
ES2494190T3 (es) * 2011-11-16 2014-09-15 Adrenomed Ag Anticuerpo anti-adrenomedulina (ADM) o fragmento de anticuerpo anti-ADM o andamiaje proteico sin Ig anti-ADM para reducir el riesgo de mortalidad en un paciente que padece una enfermedad crónica o aguda o un estado agudo
US9140696B2 (en) 2011-11-16 2015-09-22 Adrenomed Ag Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-IG scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
PL3553084T3 (pl) * 2011-11-16 2023-04-17 Adrenomed Ag Przeciwciało przeciwko adrenomedulinie (adm) lub fragment przeciwciała przeciwko adm lub szkielet przeciwko adm inny niż ig do profilaktyki lub zmniejszania zaburzenia czynności narządu lub niewydolności narządu u pacjenta cierpiącego na przewlekłą lub ostrą chorobę lub ostry stan
HRP20190122T1 (hr) 2011-11-16 2019-03-08 Adrenomed Ag Protutijelo protiv adrenomedulina (adm) ili fragment protutijela protiv adm ili okosnica ne-ig protiv adm, namijenjeni reguliranju ravnoteže tekućina kod pacijenta s kroničnom ili akutnom bolešću
HRP20191771T1 (hr) 2011-11-16 2019-12-27 Adrenomed Ag Anti-adrenomedulin (adm) antitijelo ili fragment anti-adm antitijela ili anti-adm non-ig skela za uporabu u terapiji akutne bolesti ili akutnog stanja pacijenta za stabiliziranje cirkulacije
WO2014147153A1 (en) * 2013-03-20 2014-09-25 Sphingotec Gmbh Adrenomedullin to guide therapy of blood pressure decline

Also Published As

Publication number Publication date
RU2020115794A (ru) 2021-11-19
JP2021500548A (ja) 2021-01-07
US20220268761A1 (en) 2022-08-25
BR112020005682A2 (pt) 2020-10-20
CN111480076A (zh) 2020-07-31
EP3698134A1 (en) 2020-08-26
CA3079112A1 (en) 2019-04-25
AU2018350861A1 (en) 2020-04-09
WO2019077082A1 (en) 2019-04-25
SG11202002268XA (en) 2020-04-29
RU2020115794A3 (es) 2022-01-27

Similar Documents

Publication Publication Date Title
CA211013S (en) Vaporizer device
MX2020003441A (es) Transmision de referencia de sondeo.
MX2020004287A (es) Procesamiento de biomasa.
SI4074703T1 (sl) Piridinil-(aza)indolsulfonamidi
MX2020003770A (es) Terapias de combinacion para tratar cancer.
MX2019004500A (es) Terapia de combinación para la inhibición de componente de complemeto (c3).
EP4501218A3 (en) Devices, systems and methods for using and monitoring medical devices
CA185542S (en) Table
SG11202002268XA (en) Therapy monitoring under treatment with an anti-adrenomedullin (adm) binder
MX2020003440A (es) Red de seguridad.
MX2020004241A (es) Conector y montaje de conector.
PT3678714T (pt) Dispositivo médico obtido por engenharia de tecidos
EP4233911A3 (en) Wound healing medicament
MX2022007955A (es) Regimenes de dosificacion de erdafitinib.
MX2020004424A (es) Formulacion aerosolizable.
MX2018008407A (es) Dispositivo secundario.
PH12021550102A1 (en) Cardiosafe antidiabetic therapy
CA191190S (en) Transcutaneous neuromodulatton device
MA40457A (fr) Combinaison de médicaments pour traiter le myélome multiple
MX2020003617A (es) Dispositivo de preparacion de cables.
SG11202010676TA (en) Improved t-cell therapy
MX2019015167A (es) Farmacos antivirales.
MX2020004285A (es) Proceso para preparar el benzotiofen-2-il boronato.
PH12017500071A1 (en) Therapeutic agent for keratoconjunctive disorder
MX2020003575A (es) Nuevos derivados de alcoxiamino para tratar dolor y estados relacionados con dolor.